AS1810722 is an orally active and potent STAT6 inhibitor(IC50 :1.9 nM). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:62.5 mg/mL (130.89 mM)

STAT6:1.9 nM

AS1810722 showed potent STAT6 inhibition and a good CYP3A4 inhibition profile.?AS1810722 also inhibited in vitro Th2 differentiation without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration.